Palo Alto – December 10, 2015 –Cooley advised Cour Pharmaceutical on its partnership with Takeda Pharmaceutical to research and develop novel immune therapies for the potential treatment of celiac disease and other gastrointestinal diseases.
According to Takeda's press release: "The partnership will focus on using nanotechnologies based on Cour's Tolerizing Immune Modifying nanoparticle (TIMP) platform."
Cour will receive upfront and success-based milestone payments from Takeda leading to an exclusive option to acquire a global license to the TIMP program after the completion of the Phase 2a clinical trial. Cour will also receive royalties on sales of any successful commercialized products resulting from the partnership. Takeda will have the option to collaborate on up to three additional TIMP compounds each with development, regulatory, and sales milestones and royalties on sales.
Cour is a private development stage pharmaceutical company harnessing the power of nano-biotechnology to create novel therapeutics addressing difficult-to treat immune diseases. Takeda is a global research-based pharmaceutical company and is a leader in gastroenterology.
The Cooley team advising Cour on its partnership agreement included Lila Hope and Jennifer Raab. Erich Veitenheimer, Mike Garelick and Alyson Fuller advised Cour on the IP diligence.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 850 lawyers across 12 offices in the United States, China and Europe